Business Segment Information

3 Months Ended

Jan. 31, 2022

Segment Reporting [Abstract]

Business Segment Information

Business Segment Information

The Company discloses information about its operating segments, which were established based on the way that management organizes segments within the Company for making operating decisions and assessing financial performance. The Company's two operating segments are described below.

•CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. CooperVision designs its products to solve vision challenges such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues, with a broad collection of spherical, toric and multifocal contact lenses.

•CooperSurgical. Competes in the general health care market with a focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women's health and fertility.

The Company uses operating income, as presented in our financial reports, as the primary measure of segment profitability. The Company does not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. The Company uses the same accounting policies to generate segment results as the Company does for consolidated results.

Total identifiable assets are those used in continuing operations except cash and cash equivalents, which the Company includes as corporate assets.

Segment information:

Three Months Ended January 31,
(In millions)	2022		2021
CooperVision net sales by category:
Toric lens	$	182.2	$	162.3
Multifocal lens	65.8		57.7
Single-use sphere lens	167.0		146.0
Non single-use sphere, other	146.5		141.0
Total CooperVision net sales	$	561.5	$	507.0
CooperSurgical net sales by category:
Office and surgical products	$	128.9	$	103.5
Fertility	96.8		70.0
CooperSurgical net sales	225.7		173.5
Total net sales	$	787.2	$	680.5
Operating income (loss):
CooperVision	$	127.4	$	127.5
CooperSurgical	15.6		17.5
Corporate	(12.2)		(11.6)
Total operating income	130.8		133.4
Interest expense	6.6		6.4
Other expense (income), net	2.3		(12.5)
Income before income taxes	$	121.9	$	139.5

(In millions)	January 31, 2022		October 31, 2021
Total identifiable assets:
CooperVision	$	6,918.8	$	6,965.9
CooperSurgical	4,391.8		2,395.6
Corporate	351.9		244.7
Total	$	11,662.5	$	9,606.2

Geographic information:

Three Months Ended January 31,
(In millions)	2022		2021
Net sales to unaffiliated customers by country of domicile:
United States	$	365.3	$	313.1
Europe	250.4		220.8
Rest of world	171.5		146.6
Total	$	787.2	$	680.5

(In millions)	January 31, 2022		October 31, 2021
Net property, plant and equipment by country of domicile:
United States	$	758.1	$	737.5
Europe	364.9		377.2
Rest of world	238.5		232.9
Total	$	1,361.5	$	1,347.6